New combo therapy shows promise for tough ovarian cancer
NCT ID NCT04938583
First seen Apr 08, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tests a combination of drugs (oregovomab, bevacizumab, paclitaxel, carboplatin) in adults with a specific type of recurrent ovarian cancer that has returned after initial treatment. The goal is to see if the combo is safe and shrinks tumors. About 54 participants with BRCA-wild type cancer will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Hospital
Seoul, Seoul, 05505, South Korea
-
CHA Bundang Medical Center
Seongnam-si, 13496, South Korea
-
Korea Anam Hospital
Seoul, Seoul, 02841, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Seoul St. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.